Deepak Srivastava, M.D., the director of the Gladstone Institute of Cardiovascular Disease and professor of biochemistry at the University of California, San Francisco, will be joining our panel for the upcoming biotech executive breakfast in San Francisco April 13. One of the scientific founders of iPierian, Dr. Srivastava has been preparing to advance his stem cell work into a Phase II study for ischemic damage. And he is playing a key role developing new technologies that promise to have a profound impact on the way developers think about clinical development work.
Dr. Srivastava will be joining several clinical trial experts for a discussion on study trends and technologies, with a particular focus on designing the ideal Phase II study. I'm looking forward to exploring the subject with Gisela Schwab, the CMO at Exelixis (XL184, or cabozantinib), Mathai Mammen, co-founder and SVP of R&D at Theravance (which is partnered on the late-stage respiratory drug Relovair with GlaxoSmithKline) and Susan Molineaux, the CEO of Calithera Biosciences (and former CEO of Proteolix, which completed the successful mid-stage study of carfilzomib).
INC Research is a sponsor of the event and I'm happy to report that BayBio is helping spread the word. Check out the link and plan to join us at the Hotel Nikko. As we get closer to the event, I'd like to hear from you if there's anything in particular you'd like us to cover. And, of course, you'll have a chance to ask our panel questions directly at the breakfast. -- John Carroll | Follow John on twitter